Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) plunged -8.80% to finish at $0.58 in following trading session. TonixPharma (TNXP) declared that details its recently expanded product pipeline at the 9th Annual Biotech Showcase Conference. The firm said, “We are poised to begin, in the first quarter of 2017, the Phase 3 HONOR study of TNX-102 SL for military-related posttraumatic stress disorder (:PTSD). We are confident that we can report our first topline result by the fourth quarter of 2017.” The corporation has return on equity of -143.40% and while returns on assets was calculated -125.50% with 34.46% year to date performance.
How Tonix Pharmaceuticals Holding Corp. dominated Wall Street through eye-catching trend? Find Out Here Totally Free
Shares of Pfizer Inc. (NYSE:PFE) has price volatility of 1.18% in last 5 days trading session, as shares of firm closed at $33.44 by slightly down of -0.09% in last session. Shares price moving up from its 20 days moving average with 2.12% and isolated positively from 50 days moving average with 4.60%. Pfizer (PFE) reported a research collaboration contract with the Scripps Research Institute; financial terms not disclosed. Under the terms of the collaboration, Pfizer will pay a technology access fee and thereby gain access to innovative chemical synthesis technology developed at TSRI.Members of the TSRI chemistry department-Professors Phil Baran, Ph.D., Dale Boger, Ph.D., Jin-Quan Yu, Ph.D., K. Barry Sharpless, Ph.D., and others-will work alongside Pfizer scientists to adapt these chemical methods for use in creating DELs, which require stringent processes that are tolerant of the delicate DNA backbone. SRI and Pfizer may choose to expand the scope of the joint research to include other technologies relevant for enabling DEL-based drug discovery.Financial terms of the contract are not disclosed.
Watch out for the force behind Pfizer Inc. bullish run in this report? Read Considerable Report Here
Shares of Biocept, Inc. (NASDAQ:BIOC) swings by following news as it jumped up 77.45% to $1.81 in latest trading flood. Biocept (BIOC) declared that it has secured an in-network provider contract with Blue Cross Blue Shield of Texas; terms not disclosed. “Partnering with health insurers is a major focus of our business strategy, as it may increase physician access to this non-invasive technology for their patients and provide timely adjudication of claims for patients.
Securing this in-network contract is an important milestone for Biocept, as Texas is one of our largest markets and BCBSTX is the largest provider in that state. With this contract, the number of patients with in-network access to our tests has grown to approximately 185 million, with some members having access via multiple plans.”
Can Biocept, Inc. become the newest Buy stock after this news? Read Considerable Report Here